Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2041-1723

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients ; volume:10 ; number:1 ; day:25 ; month:1 ; year:2019 ; pages:1-9 ; date:12.2019
Nature Communications ; 10, Heft 1 (25.1.2019), 1-9, 12.2019

Classification: Naturwissenschaften

Creator: Cafri, Gal
Yossef, Rami
Pasetto, Anna
Deniger, Drew C.
Lu, Yong-Chen
Parkhurst, Maria
Gartner, Jared J.
Jia, Li
Ray, Satyajit
Ngo, Lien T.
Jafferji, Mohammad
Sachs, Abraham
Prickett, Todd
Robbins, Paul F.
Rosenberg, Steven A.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41467-019-08304-z

URN: urn:nbn:de:101:1-2019022400081572520766

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 22.11.0012, 12:18 AM CET

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Cafri, Gal
Yossef, Rami
Pasetto, Anna
Deniger, Drew C.
Lu, Yong-Chen
Parkhurst, Maria
Gartner, Jared J.
Jia, Li
Ray, Satyajit
Ngo, Lien T.
Jafferji, Mohammad
Sachs, Abraham
Prickett, Todd
Robbins, Paul F.
Rosenberg, Steven A.
SpringerLink (Online service)

Other Objects (12)

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer

Hochschulschrift

Oncogenic potential of rare RRAS2 mutations

Leveraging protein quaternary structure to identify oncogenic driver mutations

Small molecule inhibitors of RAS proteins with oncogenic mutations

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer

Hochschulschrift

Oncogenic potential of rare RRAS2 mutations

Leveraging protein quaternary structure to identify oncogenic driver mutations

Small molecule inhibitors of RAS proteins with oncogenic mutations

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer

Hochschulschrift

Oncogenic potential of rare RRAS2 mutations

Leveraging protein quaternary structure to identify oncogenic driver mutations

Small molecule inhibitors of RAS proteins with oncogenic mutations

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer

Oncogenic potential of rare RRAS2 mutations

Leveraging protein quaternary structure to identify oncogenic driver mutations

Small molecule inhibitors of RAS proteins with oncogenic mutations

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer

Oncogenic potential of rare RRAS2 mutations

Leveraging protein quaternary structure to identify oncogenic driver mutations

Small molecule inhibitors of RAS proteins with oncogenic mutations

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer

Oncogenic potential of rare RRAS2 mutations

Leveraging protein quaternary structure to identify oncogenic driver mutations

Small molecule inhibitors of RAS proteins with oncogenic mutations

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

Related objects

Reset password